Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Dare Bioscience Inc (NASDAQ: DARE) is a clinical-stage biopharmaceutical leader advancing innovative therapies for women’s reproductive and sexual health. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical trial progress, regulatory milestones, and strategic partnerships.
Track the latest developments across DARE’s pipeline of non-hormonal contraceptives, sexual health treatments, and cervical health solutions. Our curated news collection includes updates on FDA submissions, trial results for candidates like Ovaprene® and Sildenafil Cream 3.6%, and collaborations advancing women’s healthcare innovation.
Key focus areas include progress toward addressing unmet needs in bacterial vaginosis treatment, female sexual arousal disorder (FSAD), and HPV-related cervical conditions. Bookmark this page for real-time access to earnings announcements, research publications, and licensing agreements that shape DARE’s position in the biopharma sector.
Daré Bioscience (NASDAQ: DARE) will host a live webinar on November 17, 2025 to review clinical data and commercial launch readiness for DARE to PLAY™ Sildenafil Cream, a first-of-its-kind topical sildenafil formulation for women. Clinical results cited show increased genital blood flow within 10–15 minutes of application and improvements in arousal on clinically validated, FDA-reviewed endpoints. The company said commercial availability is anticipated via a 503B outsourcing facility, expected before year-end, and webinar attendees can join a product alert list to be notified when the prescription product becomes available.
Daré Bioscience (NASDAQ: DARE) will host a third quarter 2025 financial results conference call and live webcast on Thursday, November 13, 2025 at 4:30 p.m. ET to review results for the quarter ended September 30, 2025 and provide a company update.
Participants can join by phone at (646) 307-1963 or (800) 715-9871 (toll-free) with conference ID 5794075. The live webcast is available in the Investors > Presentations, Events & Webcasts section at http://ir.darebioscience.com. The webcast archive will be available for replay through November 27, 2025. Attendees are advised to log in 5-10 minutes early to register and install any required software.
Daré Bioscience (NASDAQ: DARE) announced on November 3, 2025 that it has a contract with the Gates Foundation to receive up to $300,000 to conduct a global strategic landscape assessment of organizations with capabilities relevant to contraceptive product development.
Under the contract Daré will identify and assess for-profit and non-profit organizations worldwide with demonstrated capabilities in formulation development, clinical and commercial manufacturing, clinical trial design, and regulatory support for contraceptive products. The project is presented as part of Daré’s effort to strengthen the contraceptive innovation ecosystem and identify potential strategic partners to accelerate product translation.
Daré Bioscience (NASDAQ: DARE) received a $4.0 million non-dilutive grant installment on Oct 6, 2025 for DARE-LARC1, the contraception use case of its programmable DARE-IDDS implantable drug-delivery platform. Total grant funding received is approximately $41.8 million of an up-to-approximately $49 million commitment, with up to $7.1 million remaining contingent on milestones. DARE-LARC1 is preclinical and uses levonorgestrel; the platform is described as capable of programmable, wireless dosing and is being explored for obesity, diabetes, and other chronic conditions. Daré is pursuing strategic partnerships and IND-enabling studies toward an FDA IND submission.
Daré Bioscience (NASDAQ: DARE) has secured a grant of up to $499,000 from the Gates Foundation to support preeclampsia research initiatives. The company will provide strategic mentorship and project management support to Grand Challenges grantee organizations worldwide, focusing on prevention, diagnosis, and treatment of preeclampsia.
The multi-year engagement aims to advance research addressing this critical maternal health condition that claims approximately 76,000 maternal and 500,000 infant lives annually. Currently, there are no FDA-approved treatments for preeclampsia, making this initiative particularly significant for advancing women's health solutions.
Daré Bioscience (NASDAQ:DARE) reported Q2 2025 financial results and provided significant updates on its women's health product pipeline. The company is preparing to launch DARE to PLAY™ Sildenafil Cream in Q4 2025 through a 503B compounding pathway, marking its first revenue-generating product. The company reported $5.0 million in cash with a working capital deficit of $12.6 million, but strengthened its position post-quarter with $17.6 million from stock sales and a $6.0 million grant.
Key developments include positive interim results for Ovaprene® Phase 3 study, advancement of grant-funded programs for HPV treatment and long-acting contraception, and plans to commercialize vaginal probiotics and hormone therapy products. R&D expenses decreased 71% year-over-year to $1.4 million, while G&A expenses remained stable at $2.4 million.
Daré Bioscience (NASDAQ: DARE), a biopharmaceutical company focused on women's health solutions, has scheduled its Q2 2025 financial results conference call and webcast for August 14, 2025 at 4:30 p.m. ET.
Investors can join via phone at (646) 307-1963 or toll-free at (800) 715-9871 using conference ID 2684883. The webcast will be available on the company's investor relations website and archived until August 28, 2025.
Daré Bioscience (NASDAQ: DARE) and Rosy Wellness have announced the launch of a consumer awareness campaign for DARE to PLAY™ Sildenafil Cream, a groundbreaking topical formulation for women's arousal targeted for prescription availability in Q4 2025.
The campaign leverages Rosy's platform of 250,000+ women and includes an Arousal Collection and educational "Quickie" videos featuring expert Dr. Sameena Rahman. The product contains sildenafil (Viagra's active ingredient) and is clinically proven to improve genital blood flow and sexual response. This collaboration marks the first phase of a broader initiative that will include healthcare provider awareness and customer support programs.
DARE to PLAY™ will be available as a compounded drug under Section 503B of the FDCA, representing a significant advancement in women's sexual health treatment backed by clinical evidence.
Daré Bioscience (NASDAQ: DARE) announced a live webinar scheduled for August 6, 2025, to showcase DARE to PLAY™, their innovative sildenafil cream for female sexual arousal. The product, containing the same active ingredient as Viagra®, is the first and only evidence-backed sildenafil cream formulation for women, designed to improve genital blood flow and sexual response.
The webinar will feature prominent sexual health experts, including Dr. Irwin Goldstein, discussing clinical evidence and the product's proprietary formulation. DARE to PLAY™ is expected to be available by prescription in Q4 2025. The event, hosted in collaboration with The National Association of Nurse Practitioners in Women's Health, is open to clinicians, investors, and women interested in science-based sexual health solutions.
Daré Bioscience (NASDAQ: DARE) announced positive interim Phase 3 results for Ovaprene®, their investigational hormone-free monthly intravaginal contraceptive. The Data Safety Monitoring Board recommended continuing the study without modifications after reviewing safety data.
Key interim findings show a 9% pregnancy rate among treated women, aligning with pre-pivotal study expectations. While 17% of participants discontinued due to vaginal odor, no serious safety concerns were identified. The ongoing multicenter study targets 250 participants for 12-month use evaluation.
Bayer holds rights to obtain exclusive U.S. commercialization through a $20 million payment post-trial completion, with potential earnings of up to $310 million in commercial milestones plus double-digit tiered royalties.
FAQ
What is the current stock price of Dare Bioscience (DARE)?
What is the market cap of Dare Bioscience (DARE)?
